related_education

HIV Elder Study

The goal of this study is to determine the efficacy of mindfulness based stress reduction (MBSR) to alleviate stress, anxiety and depressive symptoms and improve attention among patients aged 60 or older who suffer from HIV-associated neurocognitive disorders (HAND) and have maximized treatment options.

Summary

Family Advisory Council

To promote ideal family and patient-centered care in dementia, the UCSF Memory and Aging Center has created a Family Advisory Council that provides family caregiver input regarding the delivery of clinical care services.

To promote ideal family and patient-centered care in dementia, the UCSF Memory and Aging Center has created a Family Advisory Council that provides family caregiver input regarding the delivery of clinical care services. Topics may include feedback regarding the existing services as well as ideas regarding new innovative programs under development or raising awareness regarding the priorities or unmet needs of families and patients at the MAC. The council is comprised of family caregivers who care, or have cared, for persons with dementia.

Alzheimer’s Disease Trial with Aducanumab

The primary purpose of this study is to find out whether aducanumab has the potential to be a helpful treatment that slows down disease progression in subjects with early Alzheimer’s disease (AD) by comparing it to placebo and to evaluate its safety (side effects), and to find out more about aducanumab.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Biogen
  • Recruiting?: Yes
  • Official study title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer's Disease

Progressive Supranuclear Palsy Trial with C2N-8E12

The primary purpose of this study is to determine the safety, tolerability, and maximally tolerated dosage of C2N-8E12, and anti-tau monoclonal antibody. C2N-8E12 is an immunotherapy (antibody) drug designed to bind to and to remove tau protein. The tau protein is believed to build up to abnormally high levels in the brains of individuals with PSP. This abnormal accumulation is associated with clinical progression of the disease.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: C2N Diagnostics
  • Recruiting?: Yes
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects with Progressive Supranuclear Palsy

Progressive Supranuclear Palsy Trial with BMS-986168

The primary purpose of this study is to see how safe and well tolerated the study drug BMS-986168 is at different drug amounts in patients with PSP and to measure the amount of study drug in subject’s blood and cerebrospinal fluid (CSF) after taking the drug.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Bristol-Myers Squibb Company (BMS)
  • Recruiting?: Yes
  • Official study title: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy (PSP)

Sleep and Cognition in Older Adults

The purpose of this study is to determine how sleep is affected in both healthy aging and neurodegenerative processes. The study aims to determine whether sleep quality alters performance on cognitive tasks in older adults and whether this relationship changes with mild to moderate cognitive impairments.

Summary

  • Study director: Christine Walsh, PhD
  • Sponsor: National Institute of Health (NIH) and the Tau Research Consortium
  • Recruiting?: Yes
  • Official study title: The Relationship Between Sleep and Cognition in Older Adults

Join a Supportive Care Trial

Quality of Life Trials or Supportive Care Trials are research studies to evaluate improving the health, care or quality of life for people, typically without using study drugs or devices. UCSF's Memory and Aging Center (MAC) runs selected supportive trials for people with neurodegenerative disease. Your participation helps us evaluate these interventions. If one of our trials looks interesting to you, please talk with your doctor or contact the study team to see if it is appropriate for you.

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

The goal of this study is to support the development of FTLD therapies through a multi-site research consortium headquartered at UCSF. The study aims to determine the clinical, genetic, and biomarker profiles of FTLD syndromes where there is a strong correlation between clinical syndrome and underlying pathology (FTD-ALS, PSP, and semantic variant PPA (svPPA)). The study also aims to determine the natural history of familial FTLD using novel clinical measures.

Summary

  • Study directors: Adam Boxer, MD, PhD and Howard Rosen, MD
  • Sponsor: National Institutes of Health (NIH)
  • Recruiting?: Yes
  • Official study title: Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

Progressive Supranuclear Palsy Trial of Oral Salsalate

Salsalate has been marketed for decades in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorders, but this is the first time salsalate will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of oral salsalate in people with PSP.

Summary

  • Study director: Adam Boxer, MD, PhD
  • Funder: Tau Consortium
  • Recruiting?: Yes
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
  • ClinicalTrials.gov identifier: NCT02422485

Progressive Supranuclear Palsy Trial of Plasma Transfusions

Young healthy male donor plasma is commonly used to correct clotting deficiencies, but this is the first time it will be studied in people with PSP. The purpose of this study is to determine the safety and tolerability of donor plasma transfusions in patients with PSP.

Summary

  • Study director: Richard Tsai, MD, MBA
  • Funder: Tau Consortium
  • Recruiting?: Yes
  • Official study title: A 6-Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy
Syndicate content